ZECHENG ELECTRONICS
837821
Ji Yao Holding Group
300108
Shenzhen Bestek Technology
300822
Jiangsu Canlon Building Materials
300715
Shanghai Hajime Advanced Material Technology
301000
CN Stock MarketDetailed Quotes
603567 HeiLongJiang ZBD Pharmaceutical
- 10.98
- -0.11-0.99%
Market Closed Jan 9 15:00 CST
10.33BMarket Cap15.82P/E (TTM)
11.12High10.92Low37.35KlotVolume11.09Open11.09Pre Close41.14MTurnover0.40%Turnover Ratio21.87P/E (Static)941.14MShares13.6352wk High1.33P/B10.32BFloat Cap8.6952wk Low12.20Limit Up939.54MShs Float58.82Historical High9.98Limit Down1.80%Amplitude8.69Historical Low0.20Dividend TTM11.02Avg Price22.66KlotAsk1.82%Div YieldTTM100Lot Size13.49KlotBid
HeiLongJiang ZBD Pharmaceutical News
Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing
ZBD Pharma Gets China Approval for Antibacterial Injection
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Price Dropped 3.8% Last Week; Private Equity Firms Would Not Be Happy
Report for the third quarter of 2024 of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
While Shareholders of Heilongjiang ZBD Pharmaceutical (SHSE:603567) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown
We Think Heilongjiang ZBD Pharmaceutical (SHSE:603567) Can Stay On Top Of Its Debt
China Rejects ZBD Pharmaceutical's Application For Skin Infection Drug
Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
Improved Earnings Required Before Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHSE:603567) Shares Find Their Feet
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Annual Report 2023 - Revised Edition Summary.
Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Semi-Annual Report - Revised Edition Summary.
Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1/2024 Revised Report
Heilongjiang ZBD Pharmaceutical Co., Ltd. Annual Report 2023 - Revised Edition.
Heilongjiang ZBD Pharmaceutical Co., Ltd. 2023 Interim Report - Revised Version.
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Q3 2023 Revised Report
Heilongjiang ZBD Pharmaceutical Co., Ltd. Q1 2023 Revised Report
Private Equity Firms Are Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Biggest Owners and Were Hit After Market Cap Dropped CN¥517m
ZBD Pharmaceutical Gets Nod to Market Bromhexine Hydrochloride Injection
ZBD Pharmaceutical Gets Nod to Trial Qingjianghewei Granules